Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Julphar
Cantor Fitzgerald
Healthtrust
Queensland Health
Federal Trade Commission
McKesson
Teva
UBS

Generated: April 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,550,165

« Back to Dashboard

Summary for Patent: 5,550,165
Title: Pharmaceutical compositions for the treatment of hereditary tyosinemia type I
Abstract:The invention concerns novel pharmaceutical compositions containing as an active ingredient a 2-benzoyl-1,3-cyclohexanedione which is an inhibitor of the enzyme 4-hydroxyphenylpyruvate dioxygenase (HPPD). The compositions are valuable in the treating those disorders and diseases in which it is desirable to intervene in the metabolic sequences catalysed by HPPD, such as in treating tyrosinemia type I.
Inventor(s): Ellis; Martin K. (Macclesfield, GB2), Lindstedt; Sven T. (Lund, SE), Lock; Edward A. (Wilmslow, GB2), Markstedt; Maj E. H. (Billdal, SE), Mutter; Linda C. (Bloomfield, CA), Prisbylla; Michael P. (Richmond, CA)
Assignee: Zeneca Limited (London, GB2)
Application Number:08/359,361
Patent Claim Types:
see list of patent claims
Use; Composition; Compound; Formulation; Dosage form;

Drugs Protected by US Patent 5,550,165

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 5,550,165

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9113622Jun 24, 1991
United Kingdom9206412Mar 24, 1992

International Patents Family Members for US Patent 5,550,165

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 0591275 ➤ Try a Free Trial CA 2005 00029 Denmark ➤ Try a Free Trial
European Patent Office 0591275 ➤ Try a Free Trial 91180 Luxembourg ➤ Try a Free Trial
European Patent Office 0591275 ➤ Try a Free Trial SPC/GB05/030 United Kingdom ➤ Try a Free Trial
European Patent Office 0591275 ➤ Try a Free Trial 05C0024 France ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Accenture
Cipla
Medtronic
Harvard Business School
Queensland Health
QuintilesIMS
Farmers Insurance
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.